1文献来源研究一:Nakagawa K,Garon EB,Seto T,et al.Ramucirumab plus Erlotinib in patients with untreated,EGFR-mutated,advanced non-small-cell lung cancer(RELAY):A randomised,double-blind,placebo-controlled,phase 3 trial...1文献来源研究一:Nakagawa K,Garon EB,Seto T,et al.Ramucirumab plus Erlotinib in patients with untreated,EGFR-mutated,advanced non-small-cell lung cancer(RELAY):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2019,20(12):1655-1669.研究二:Zhou Q,Wu YL,Cheng Y,et al.CTONG 1509:Phase 3 study of Erlotinib with or without Bevacizumab in untreated Chinese patients with advanced EGFR-mutated NSCLC[J].Ann Oncol,2019,30(5S):v602-v660.2证据水平1b。3背景临床前和临床研究证实厄洛替尼联合抗血管生成药物具有协同作用,可显著延长表皮生长因子受体(epidermal growth factor receptor,EGFR)敏感突变晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的无进展生存期(progression-free survival,PFS)。展开更多
近年来,随着众多新的抗癌药物应用于临床,癌症治疗的费用迅速增长。然而,昂贵的医疗费用有时候并没有进一步提高治疗效果,反而增加了患者的经济负担。鉴于癌症治疗成本飙升的现状,美国临床肿瘤学会（American Society of Clinical Oncol...近年来,随着众多新的抗癌药物应用于临床,癌症治疗的费用迅速增长。然而,昂贵的医疗费用有时候并没有进一步提高治疗效果,反而增加了患者的经济负担。鉴于癌症治疗成本飙升的现状,美国临床肿瘤学会（American Society of Clinical Oncology,ASCO）急切倡议改善癌症治疗价值。展开更多
文摘1文献来源研究一:Nakagawa K,Garon EB,Seto T,et al.Ramucirumab plus Erlotinib in patients with untreated,EGFR-mutated,advanced non-small-cell lung cancer(RELAY):A randomised,double-blind,placebo-controlled,phase 3 trial[J].Lancet Oncol,2019,20(12):1655-1669.研究二:Zhou Q,Wu YL,Cheng Y,et al.CTONG 1509:Phase 3 study of Erlotinib with or without Bevacizumab in untreated Chinese patients with advanced EGFR-mutated NSCLC[J].Ann Oncol,2019,30(5S):v602-v660.2证据水平1b。3背景临床前和临床研究证实厄洛替尼联合抗血管生成药物具有协同作用,可显著延长表皮生长因子受体(epidermal growth factor receptor,EGFR)敏感突变晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的无进展生存期(progression-free survival,PFS)。
文摘近年来,随着众多新的抗癌药物应用于临床,癌症治疗的费用迅速增长。然而,昂贵的医疗费用有时候并没有进一步提高治疗效果,反而增加了患者的经济负担。鉴于癌症治疗成本飙升的现状,美国临床肿瘤学会（American Society of Clinical Oncology,ASCO）急切倡议改善癌症治疗价值。
